{
    "nctId": "NCT04982848",
    "briefTitle": "Korea Post Marketing Surveillance (PMS) Study of Talzenna\u00ae",
    "officialTitle": "A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Talzenna(Registered)",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Incidence of adverse events categorized according to physical organ and disease/symptom",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient scheduled to start treatment with Talzenna\u00ae based on the clinical judgment of their treating physician as specified in the Korean-Prescribing information (local label)\n2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\n1. Patients with known hypersensitivity to Talzenna\u00ae, or to any of the excipients.\n2. Breastfeeding\n3. Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information.",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}